company background image
THRX

Theseus Pharmaceuticals NasdaqGS:THRX Stock Report

Last Price

US$8.34

Market Cap

US$318.2m

7D

-3.9%

1Y

n/a

Updated

16 Aug, 2022

Data

Company Financials +
THRX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

THRX Stock Overview

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients.

Theseus Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Theseus Pharmaceuticals
Historical stock prices
Current Share PriceUS$8.34
52 Week HighUS$24.54
52 Week LowUS$4.86
Beta0
1 Month Change21.40%
3 Month Change13.47%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-55.11%

Recent News & Updates

Aug 11

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Theseus Pharmaceuticals press release (NASDAQ:THRX): Q2 GAAP EPS of -$0.30 in-line. Cash and cash equivalents and short-term and long-term investments of $228.6 million.

Shareholder Returns

THRXUS PharmaceuticalsUS Market
7D-3.9%0.7%3.6%
1Yn/a0.3%-9.6%

Return vs Industry: Insufficient data to determine how THRX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how THRX performed against the US Market.

Price Volatility

Is THRX's price volatile compared to industry and market?
THRX volatility
THRX Average Weekly Movement11.7%
Pharmaceuticals Industry Average Movement12.0%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: THRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: THRX's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201726Tim Clacksonhttps://theseusrx.com

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.

Theseus Pharmaceuticals Fundamentals Summary

How do Theseus Pharmaceuticals's earnings and revenue compare to its market cap?
THRX fundamental statistics
Market CapUS$318.21m
Earnings (TTM)-US$38.17m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
THRX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$38.17m
Earnings-US$38.17m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did THRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is THRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for THRX?

Other financial metrics that can be useful for relative valuation.

THRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-2.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does THRX's PB Ratio compare to its peers?

THRX PB Ratio vs Peers
The above table shows the PB ratio for THRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average11x
WVE Wave Life Sciences
10.4x19.4%US$321.2m
MNMD Mind Medicine (MindMed)
2.3x-19.3%US$290.7m
BTMD biote
27.7x6.4%US$298.1m
CBAY CymaBay Therapeutics
4x51.4%US$331.1m
THRX Theseus Pharmaceuticals
1.4x-28.1%US$318.2m

Price-To-Book vs Peers: THRX is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (11.1x).


Price to Earnings Ratio vs Industry

How does THRX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: THRX is good value based on its Price-To-Book Ratio (1.4x) compared to the US Pharmaceuticals industry average (2.1x)


Price to Book Ratio vs Fair Ratio

What is THRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

THRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate THRX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of THRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate THRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate THRX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Theseus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-28.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: THRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: THRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: THRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: THRX is forecast to have no revenue next year.

High Growth Revenue: THRX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if THRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Theseus Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-144.7%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: THRX is currently unprofitable.

Growing Profit Margin: THRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if THRX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare THRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: THRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).


Return on Equity

High ROE: THRX has a negative Return on Equity (-16.67%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Theseus Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: THRX's short term assets ($227.5M) exceed its short term liabilities ($5.2M).

Long Term Liabilities: THRX's short term assets ($227.5M) exceed its long term liabilities ($4.1M).


Debt to Equity History and Analysis

Debt Level: THRX is debt free.

Reducing Debt: THRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: THRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: THRX has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 72% each year.


Discover healthy companies

Dividend

What is Theseus Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate THRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate THRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if THRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if THRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as THRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Tim Clackson (57 yo)

1.33yrs

Tenure

US$7,093,015

Compensation

Dr. Timothy P. Clackson, also known as Tim, Ph D., is a Director at Elevation Oncology, Inc. since May 2020. Dr. Clackson serves as the Chief Executive Officer and President at Theseus Pharmaceuticals, Inc...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD7.09M) is above average for companies of similar size in the US market ($USD2.53M).

Compensation vs Earnings: Insufficient data to compare Tim's compensation with company performance.


Leadership Team

Experienced Management: THRX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: THRX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: THRX only recently listed within the past 12 months.


Top Shareholders

Company Information

Theseus Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Theseus Pharmaceuticals, Inc.
  • Ticker: THRX
  • Exchange: NasdaqGS
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$318.214m
  • Shares outstanding: 38.16m
  • Website: https://theseusrx.com

Number of Employees


Location

  • Theseus Pharmaceuticals, Inc.
  • 245 Main Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.